TransCode Therapeutics Reports Increased Losses and Strategic Acquisition in Latest 10-Q Filing

TransCode Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of approximately $4.9 million for the third quarter, compared to a loss of $2.3 million in the same period last year. For the nine months ended September 30, 2025, the net loss increased to about $21.2 million, up from $10.8 million in the prior year. The increase in losses is attributed primarily to heightened research and development expenses, which rose to $3.2 million for the quarter and $7.9 million for the nine-month period, reflecting increased clinical trial spending and drug production costs.

TransCode's total operating expenses for the third quarter were approximately $4.6 million, a significant increase from $2.2 million in the same quarter of 2024. The company’s general and administrative expenses also saw fluctuations, increasing by $462,000 in the third quarter but decreasing by $493,000 over the nine-month period compared to the previous year. The changes in expenses were influenced by various factors, including restructuring actions and adjustments in compensation and professional service fees.

In terms of strategic developments, TransCode completed a significant acquisition on October 8, 2025, acquiring 100% of ABCJ, LLC, which owns Polynoma, a biopharmaceutical company focused on an investigational vaccine for melanoma. This acquisition is expected to enhance TransCode's therapeutic portfolio, particularly in immuno-oncology. Concurrently, the company entered into an investment agreement with DEFJ, LLC, raising approximately $25 million through the issuance of Series B Non-Voting Preferred Stock, which will support ongoing operations and development efforts.

As of September 30, 2025, TransCode reported cash reserves of approximately $2.8 million, down from $5.8 million at the end of 2024. The company anticipates that its current cash position, combined with the recent funding, will be sufficient to support operations into the fourth quarter of 2026. However, TransCode acknowledges the need for additional capital to continue its research and development activities and to achieve its business objectives. The company has not generated any revenue to date and remains focused on advancing its clinical trials and product candidates, with plans to initiate a Phase 2a trial for its lead candidate, TTX-MC138, in the first half of 2026.